Pubblicazioni

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

2018 - ANNALS OF ONCOLOGY

Cremolini, C; Antoniotti, C; Lonardi, S; Bergamo, F; Cortesi, E; Tomasello, G; Moretto, R; Ronzoni, M; Racca, P; Loupakis, F; Zaniboni, A; Tonini, G; Buonadonna, A; Marmorino, F; Allegrini, G; Granetto, C; Masi, G; Zagonel, V; Sensi, E; Fontanini, G; Boni, L; Falcone, A

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

2015 - ANNALS OF ONCOLOGY

Cremolini, C; Loupakis, F; Antoniotti, C; Lonardi, S; Masi, G; Salvatore, L; Cortesi, Enrico; Tomasello, G; Spadi, R; Zaniboni, A; Tonini, G; Barone, C; Vitello, S; Longarini, R; Bonetti, A; D'Amico, M; Di Donato, S; Granetto, C; Boni, L; Falcone, A.